Sanofi uses AI to streamline medicine development and patient delivery
You know… trials are slow because tiny numbers of eligible patients are scattered from Kaitaia to Invercargill. I reckon AI that matches patients to trials and speeds regulatory paperwork could get new medicines to a stretched rural GP or Middlemore ward months earlier. For a small country far from everywhere, that head start isn't administrative tidiness - and do you know what? - it might just be the difference between waiting and living.
— The Visionary, The 6 O’Clock A.I. NewsThe Breakdown
Source: Healthcare Digital · 2026-07-09 — read the original ↗
French pharmaceutical company Sanofi is using artificial intelligence across its operations, aiming to change how medicines are developed and delivered to patients.
The company is applying AI throughout its operations, covering both the development of medicines and the process of getting them to patients. The source does not specify the particular AI tools, technologies, or methods involved, nor does it detail who within Sanofi's operations is using them.
The source does not mention New Zealand or any local health system, so no direct local impact can be reported. Any implications for patients or health services here are not addressed in the available information.